ARS Pharmaceuticals, Inc.

The momentum for this stock is not very good. ARS Pharmaceuticals, Inc. is not a good value stock. ARS Pharmaceuticals, Inc. is not a good growth stock. ARS Pharmaceuticals, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in ARS Pharmaceuticals, Inc..
Log in to see more information.
SPRY Fundamental Data by TradingView

News

ARS Pharmaceuticals (NASDAQ:SPRY) Rating Reiterated by Cantor Fitzgerald
ARS Pharmaceuticals (NASDAQ:SPRY) Rating Reiterated by Cantor Fitzgerald

Ticker Report ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report)s stock had its "overweight" rating reaffirmed by equities research analysts at Cantor Fitzgerald in a note issued to investors on Monday...\n more…

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

Globe Newswire SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...\n more…

ARS Pharmaceuticals submits sNDA to FDA for neffy 1 mg
ARS Pharmaceuticals submits sNDA to FDA for neffy 1 mg

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

Globe Newswire If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9...\n more…

ARS Pharmaceuticals, Inc. Upgraded to Buy: Here's Why
ARS Pharmaceuticals, Inc. Upgraded to Buy: Here's Why

Benzinga ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.\n more…

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why

Zacks Investment Research ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates...\n more…